Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LMRI vs MPLT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LMRI Captures Overall Composite Edge (32.1 SELL vs 48.3 HOLD), While MPLT Leads 3–1 on Growth & Valuation Pillars

LMRI Overall Winner 6-Pillar Tally: LMRI 1 – 3 MPLT (2 Tie) Matrix Metrics: LMRI 1 – 7 MPLT

As of Nov 20, 2026, LMRI (LMRI) captures the overall head-to-head institutional edge over MapLight Therapeutics, Inc. (MPLT) on higher Unified Composite conviction (32.1/100 SELL vs. 48.3/100 HOLD) after splitting the core matrix 1–7 (led by Options & Positioning), while MPLT wins 3–1 across the 6-pillar growth and valuation breakdown. LMRI trades at $14.26 (N/M Forward P/E, N/A operating margin) versus MPLT at $5.94 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MPLT currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. LMRI 32.1/100 SELL), LMRI captures the overall institutional head-to-head verdict (1–7 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. 0.0% operating margin) and revenue trajectory (N/A vs. +0.0% YoY).
  • Technical & Structure Timing Caution: LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LMRI vs MPLT
LMRI US Equity Head-to-Head Winner
LMRI
Institutional Equity
$14.26
+1.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.22β · 85% Vol
Unified Composite Score
32.1 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 63
RSI-14: 62.5 · SMA20: $13.28 · SMA50: $11.73
MPLT US Equity
MapLight Therapeutics, Inc.
Pharmaceutical Preparations
$5.94
-7.48% 1D
Market Cap $356.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.19β · 79% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 33.0 Fund 64.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.4%), weak momentum, RSI 30
RSI-14: 30.2 · SMA20: $7.08 · SMA50: $8.63

6-Pillar Scorecard Institutional Category Breakdown (LMRI 1 – 3 MPLT)

Columns: Metric · LMRI · MPLT
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale MPLT
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $356.8M
3. Profitability & Quality MPLT
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -74.2%
4. Balance Sheet & Cash Flow MPLT
Cash Generation (TTM) N/A -$179M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $54M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LMRI
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 97.5% (9th %ile)
Put/Call OI Skew N/A 1.67x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LMRI (1) vs MPLT (7)
Institutional Metric LMRI MPLT Criterion Row Edge
Market Capitalization
Scale
N/A $356.8M Larger Scale MPLT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth MPLT
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin MPLT
Net Profit Margin
Profitability
N/A 0.0% Higher Margin MPLT
Return on Equity (ROE)
Capital Efficiency
N/A -74.2% Higher ROE MPLT
52-Week Range Position
Momentum
60% ($6–$19) 0% ($6–$40) Stronger Trend LMRI
Beta / 30D Volatility
Risk Regime
1.22β · 85% Vol 1.19β · 79% Vol Lower Realized Risk MPLT
Unified Institutional Score
Composite Signal
32.1 / 100 (SELL) 48.3 / 100 (HOLD) Higher Composite MPLT
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$179M ($54M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LMRI +58.95 pp
LMRI: +30.95% · MPLT: -28.0%
3M Horizon LMRI +68.05 pp
LMRI: +20.34% · MPLT: -47.71%
6M Horizon LMRI +157.59 pp
LMRI: +78.25% · MPLT: -79.34%
1Y Horizon LMRI +47.44 pp
LMRI: -23.0% · MPLT: -70.44%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LMRI vs MPLT. Trailing 12-month operating profitability (LMRI N/A vs MPLT 0.0%) and valuation multiples (LMRI N/M vs MPLT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LMRI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
MPLT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-74.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LMRI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LMRI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MPLT BREAKDOWN
148d in phase · OBV DISTRIBUTION
Current IV 97.5%
IV Percentile 9th %ile
Put/Call OI Skew 1.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact MPLT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LMRI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MPLT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $356.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LMRI vs MPLT Key Questions & Quantitative Answers

As of Nov 20, 2026, LMRI (LMRI) captures the overall head-to-head institutional edge over MapLight Therapeutics, Inc. (MPLT) on higher Unified Composite conviction (32.1/100 SELL vs. 48.3/100 HOLD) after splitting the core matrix 1–7 (led by Options & Positioning), while MPLT wins 3–1 across the 6-pillar growth and valuation breakdown. LMRI trades at $14.26 (N/M Forward P/E, N/A operating margin) versus MPLT at $5.94 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MPLT currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. LMRI 32.1/100 SELL), LMRI captures the overall institutional head-to-head verdict (1–7 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. 0.0% operating margin) and revenue trajectory (N/A vs. +0.0% YoY). Technical & Structure Timing Caution: LMRI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.5); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MPLT leads the Growth & Scale pillar: LMRI posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with MPLT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LMRI generates N/A in USD-normalized revenue versus N/A for MPLT. In operating R&D and SG&A reinvestment, LMRI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MPLT.

LMRI and MPLT trade at balanced relative valuation multiples. LMRI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MPLT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LMRI (N/A ROE) versus MPLT (-74.2% ROE) capital efficiency.

In options market volatility and institutional positioning, LMRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 85% Vol realized risk). By comparison, MPLT carries 97.5% implied volatility (9th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.19β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.